Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert(Institut Gustave Roussy), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Maio(University of Siena), Brian J. Sharkey(Bristol-Myers Squibb (United States)), Ian M. Waxman(Apple (Israel)), Célèste Lebbé(Inserm), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Francesco Cognetti(Apple (Israel)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Catalin Mihalcioiu(McGill University Health Centre), Catriona M. McNeil(Chris O’Brien Lifehouse), Cornelia Mauch(University Hospital Cologne), L. Lundgren-Eriksson(Apple (Israel)), Henrik Schmidt(Aarhus University Hospital), Jessica C. Hassel(German Cancer Research Center), Georgina V. Long(The University of Sydney), Micaela Hernberg(Apple (Israel)), Ewa Kalinka‐Warzocha(Apple (Israel)), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Laurent Mortier, J. Charles(Apple (Israel)), Helen Gogas(National and Kapodistrian University of Athens), Benjamin Brady(Apple (Israel)), Christine E. Horak(Bristol-Myers Squibb (United States)), Ana Arance(Hospital Clínic de Barcelona), Victoria Atkinson(Greenslopes Private Hospital), Kerry J. Savage(Spinal Cord Injury BC)
Cited by 5,350
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k